Bio Tie Therapies entered into licensing agreement
Biotie Therapies entered into a licensing agreement on its VAP-1 antibody program with the Japanese company Seikagaku Corporation. The agreement is valued at USD 16.7 million, including a signing fee and milestone payments.
|  |
LAB International Licenses Fentanyl Taifun® for Japan
LAB International Inc. (“LAB”) drug development subsidiary, LAB Pharma Ltd., and Teikoku Seiyaku Co. Ltd. have entered into a licensing and development agreement for Fentanyl TAIFUN®, LAB’s fast-acting Fentanyl formulation, for the Japanese market. | 
|
Other
Licensing operation in Japan for a spin-off from a big pharmaceutical company.
Global Japanese medical equipment company for business development in Europe and USA.
Clinical development coordination in Europe for a Japanese pharmaceutical company. |  
|
A global industrial equipment company with healthcare unit for business development and licensing in Japan.
Japanese biotech venture company for out-licensing in Europe and USA. |   |
A European Academic technology transfer office for licensing operations in Japan.
Relation management services with European opinion leaders for a Japanese pharmaceutical company. |   |
Supporting Japanese biopharma company to collect funding.
European biotech company for in-licensing operation in Japan.
A leading Scandinavian diagnostic company for distribution arrangements in Japan.
Market intelligence services for a global life-science company. |   |
| Business plan development and strategic advice for a leading CNS biotech. |  |
| |   |
| |  |
